Skip to content

Brexpiprazole

SGA • Brands: Rexulti

Last reviewed: 2025-09-23

General information

Indicated for: Brexpiprazole is an atypical antipsychotic indicated for: Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults. (1 , 14.1) Treatment of schizophrenia in adults. (1 , 14.2)

Dosing & forms

  • Forms/strengths: —
  • Frequency: —
  • Food: —
  • Typical range: 1–4 mg/day

Mechanism (brief)

D2/D3 partial agonist; 5‑HT1A partial agonist; 5‑HT2A antagonist.

Metabolism & Half‑life

  • Metabolism: CYP3A4 and CYP2D6, dose adjust with inhibitors/inducers.
  • Half‑life: ~91 h (long).

Therapeutic Drug Monitoring (TDM)

Recommended: No

View labelExact

Monitoring highlights

  • Metabolic: weight, BMI, fasting lipids/glucose — Baseline, 3 mo, annually

Sources